Clinical Financial Services (CFS) Launches New Service to Streamline Clinical Trial Activation
As part of its ongoing mission to provide comprehensive business and financial management solutions in support of clinical trials, Clinical Financial Services (CFS) is pleased to announce the launch of its newest offering, Site Activation Services. This new service, which includes regulatory document collection and management as well as global investigator budget and contract management, will streamline and automate the trial activation process and minimize financial risk for clinical trial sponsors, CROs, and investigative sites.
Headed by a team dedicated to managing the complex tasks required to activate investigator sites, CFS can accelerate clinical trial cycle times by maximizing the number of sites that are activated and "enrollment ready" when the enrollment phase of the trial begins.
- By pre-populating regulatory and financial disclosure documents with data from an enterprise-wide proprietary database, CFS ensures the accuracy of site and investigator information, prevents redundancy and speeds the time it takes to complete this paperwork.
- Through extensive audit capabilities, CFS ensures that financial disclosure information is compliant with 21CFR Part 54 and internal SOPs, consistent with Form FDA 1572 and aligned with aggregate spend payment data.
- With a global legal network operating in more than 60 countries, CFS supports complex contract negotiations around the world.
- By offering a technologically advanced project dashboard that is available 24/7, CFS offers unprecedented visibility into the status of every trial start-up document.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
